A Study to Evaluate Pneumococcal Polysaccharide Vaccine Effectiveness in Children With Type 1 Diabetes

Mayo Clinic29 enrolled

Overview

The purpose of this study is to determine if children with type 1 diabetes have adequate immune response to PPSV23 vaccination and to assess factors affecting immune response.

Study Type

INTERVENTIONAL

Allocation

Purpose

PREVENTION

Masking

NONE

Enrollment

Conditions

Type 1 Diabetes

Interventions

Pneumovax 23- pneumococcal polysaccharideBIOLOGICAL

PPSV23 is a vaccine to help protect against serious infection due to the Streptococcus pneumoniae bacteria. One dose administered intramuscularly or subcutaneously.

Blood drawPROCEDURE

6 ml blood draw at baseline and 6 months post immunization

Eligibility

Sex: ALLMin age: 3 YearsMax age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Children ages 3-18 years old. * Clinical diagnosis of Type 1 diabetes. Exclusion Criteria: * Newly diagnosed with Type 1 diabetes with in the past month of study date. * Contraindications to receiving 23 valent pneumococcal vaccines. * Other conditions associated with compromised immunity and vaccine response. * Primary or Secondary Immune deficiency. * Previous receipt of PPSV-23 vaccination.

Locations (1)

Mayo Clinic in Rochester

Rochester, Minnesota, United States

Outcomes

Primary Outcomes

Immunoglobulin G (IgG) Antibodies

Serological response. Blood draw for assessment of pneumococcal specific titer IgG. Measured as mcg/mL

Time frame: 6 months post vaccination

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.